131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.
The aim of this document is to provide general information about mIBG scintigraphy in cancer patients. The guidelines describe the mIBG scintigraphy protocol currently used in clinical routine, but do not include all existing procedures for neuroendocrine tumours. The guidelines should therefore not be taken as exclusive of other nuclear medicine modalities that can be used to obtain comparable results. It is important to remember that the resources and facilities available for patient care may vary from one country to another and from one medical institution to another. The present guidelines have been prepared for nuclear medicine physicians and intend to offer assistance in optimizing the diagnostic information that can currently be obtained from mIBG scintigraphy. The corresponding guidelines of the Society of Nuclear Medicine (SNM) and the Dosimetry, Therapy and Paediatric Committee of the EANM have been taken into consideration, and partially integrated into this text. The same has been done with the most relevant literature on this topic, and the final result has been discussed within a group of distinguished experts.
Bombardieri
Emilio
E
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Giammarile
Francesco
F
Aktolun
Cumali
C
Baum
Richard P
RP
Bischof Delaloye
Angelika
A
Maffioli
Lorenzo
L
Moncayo
Roy
R
Mortelmans
Luc
L
Pepe
Giovanna
G
Reske
Sven N
SN
Castellani
Maria R
MR
Chiti
Arturo
A
D019797:3-Iodobenzylguanidine; D006801:Humans; D008495:Medical Oncology / Q000592:standards*; D009369:Neoplasms / Q000000981:diagnostic imaging*; D009683:Nuclear Medicine / Q000592:standards*; D011877:Radionuclide Imaging / Q000592:standards*; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine